Narkotikų sukeliamos žalos mažinimo programų teisinis reglamentavimas ES ir nacionalinėje teisėje

Abstract

The main object of drug and psychotropic substance harm reduction programs is to diminish drug usage and negative influence of injective drugs that they have on separate individuals, their families and all community including crime and infection transmission. The programs attempt to draw drug users and their partners to health and social service institutions in order to diminish drug overdosing or death risks caused by drug abuse as well as to encourage drug users to be healed and integrated into the community. The substitutive healing and syringe change programs which are widely applied in Lithuania are not effective. Researches indicate that these programs do not reduce drug usage and on individual cases increase it. Therefore such programs should be terminated and alternative means to diminish drug harm must be created. Substitutive healing, such as methadon or other drug healing, must be changed to alternative programs. The efforts of the healing institutions and organisations to heal drug users without alternative drug usage and preparation of qualified specialists to heal secondary drug dependance in regard to substitutive healing, must be supported. Inspite of the fact that law regulation acts in EU countries establish drug harm reduction programs, Lithuania should firmly keep to it’s possition and terminate application of such programs in Lithuania. This essay consists of introduction, four chapters divided to smaller paragraphs, conclusion, literature list and summary in English language. The first chapter is dedicated to present the conception of drug harm reduction, it’s sources and historical evolution. The analysis of separate drug harm reduction programs is presented in the second chapter. The third chapter is dedicated to the analysis of national law system in Lithuania. Individual law regulations dedicated to the drug harm reduction program application are overviewed in this chapter. The specialities of drug harm reduction programs in EU law regulation acts are reviewed in the fourth chapter.